WuXi AppTec stock analysis 2026 | Price, valuation & outlook

WuXi AppTec

SHSE:603259

¥ 99,99

¥-3,20 (-3,10%)

99,99 ¥

¥-3,20 (-3,10%)

End-of-day quote: 04/03/2026

WuXi AppTec Stock Value

Analysts currently rate SHSE:603259 as Buy.

Buy

WuXi AppTec Company Info

EPS Growth 5Y

40,36%

Market Cap

¥311,12 B

Long-Term Debt

¥1,82 B

Annual earnings

N/A

Dividend

¥1,87

Dividend Yield

1,87%

Founded

2000

Industry

Health Care

Country

China

Website

WuXi AppTec

ISIN Number

CNE1000031K4

Website

http://www.wuxiapptec.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

¥135,00

35.01%

Last Update: 04/03/2026

Analysts: 18

Highest Price Target ¥152,00

Average Price Target ¥135,00

Lowest Price Target ¥112,21

In the last five quarters, WuXi AppTec’s Price Target has risen from ¥29,73 to ¥68,33 - a 129,84% increase. Fiveteen analysts predict that WuXi AppTec’s share price will increase in the coming year, reaching ¥135,00. This would represent an increase of 35,01%.

Top growth stocks in the health care sector (5Y.)

What does WuXi AppTec do?

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies. Business Segments The company operates through business segments: WuXi Chemistry, WuXi Biology, WuXi Testing, WuXi ATU and WuXi Discovery Service Unit. WuXi Chemistry This segment focuses on contract research and development, offering services that include synthetic chemistry, medicinal chemistry, an...

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies.

Business Segments

The company operates through business segments: WuXi Chemistry, WuXi Biology, WuXi Testing, WuXi ATU and WuXi Discovery Service Unit.

WuXi Chemistry

This segment focuses on contract research and development, offering services that include synthetic chemistry, medicinal chemistry, and scale-up processes. By leveraging a well-structured approach to integrating chemistry-related resources, WuXi Chemistry aids in the execution of various phases of the drug development process.

WuXi Biology

This division harnesses innovative technologies and expertise in biology, particularly in areas such as cell biology, immunology, and oncology. WuXi Biology delivers a vast range of integrated services, contributing significantly to drug discovery via in vitro and in vivo models.

WuXi Testing

This segment encompasses preclinical and clinical testing, this segment integrates capabilities for laboratory testing, clinical development, and site management services. This structure ensures that the company can provide its global clientele with reliable, data-driven insights while ensuring compliance with necessary regulatory standards.

WuXi ATU (Cell and Gene Therapy)

WuXi ATU capitalizes on its experience in the cell and gene therapy sector, providing comprehensive contract testing, development, and manufacturing organization services. This segment reflects the company’s adaptability to the evolving landscape of therapeutic modalities that leverage genetic engineering technologies.

WuXi Discovery Service Unit (WuXi DDSU)

Tailored based on customer specifications, WuXi DDSU emphasizes collaborative discovery efforts, providing tailored solutions for complex drug discovery programs.

Business Strategy

The company employs a multifaceted business strategy aimed at sustaining growth in a dynamic market environment. This strategy is fundamentally anchored in a commitment to innovation and the provision of high-quality services that align with the evolving demands of the pharmaceutical and biotechnology markets.

To achieve operational excellence, the company focuses on expanding its service offerings across the entire drug development lifecycle. By continuously enhancing its research and development capabilities, the company can offer new technologies and techniques that help clients overcome the challenges associated with drug development.

Moreover, the company seeks to establish robust partnerships and collaborations across the industry. By forging strategic alliances with other leading entities, both academic and corporate, the company enhances its knowledge base while simultaneously broadening its service capabilities.

Finally, the company prioritizes geographic expansion to tap into emerging markets and progress further into established markets. The localization of services and knowledge provides a significant edge, enabling the company to cultivate stronger relationships with a wider spectrum of customers globally.

Products and Services

The company offers a comprehensive suite of products and services designed to meet the diverse needs of clients in the pharmaceutical and biotechnology industries. These services are paramount in supporting both the drug discovery and development processes.

Small Molecule Development Services: This includes synthesis, analytical services, and CRDMO offerings tailored to the needs of clients engaged in small molecule drug discovery and development.

Biologics Development: Through extensive laboratory capabilities, the company provides processes that support the development of biologics, including monoclonal antibodies, proteins, and vaccines. Comprehensive testing and method development services are also integral components of this offering.

Analytical Testing Services: The company offers robust analytical services, which encompass method development, validation, and stability testing, ensuring clients attain regulatory compliance while optimizing their products.

Preclinical and Clinical Services: The company facilitates the progression of drug candidates through preclinical and clinical trials by providing necessary testing services, including laboratory experiments and management of clinical trials.

Gene and Cell Therapy Services: Capitalizing on pioneering techniques, the company provides tailored CTDMO services, including testing for cell and gene therapies.

Beyond these primary services, the company incorporates information technology solutions to manage data comprehensively, ensuring clients are equipped with vital insights throughout the drug development journey.

Geographical Markets Served

The company operates globally, with a presence in North America, Europe, and Asia. This geographic reach allows the company to serve clients across a wide range of markets while accessing diverse regulatory landscapes.

Customers

The company serves a broad spectrum of clients, encompassing multinational pharmaceutical companies, biotechnology firms, medical device manufacturers, and academic institutions. The diversity of customer categories includes established global enterprises to emerging biotech companies, with the total number of active clients reaching thousands worldwide.

Sales and Marketing

The company employs a multifaceted marketing approach to reach potential clients, which includes direct sales, digital marketing, participation in industry conferences, and strategic partnerships. The company’s sales teams are adept at providing tailored solutions to clients, emphasizing collaboration and partnership to foster long-term relationships.

History

WuXi AppTec Co., Ltd. was founded in 2000. The company was incorporated in 2017.

WuXi AppTec Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical services:** 60% **Biotechnology:** 25% **Chemical research and development:** 15% **TOP 3 markets:** **USA:** 40% **China:** 35% **Europe:** 15% WuXi AppTec Co., Ltd. generates the majority of its revenue from pharmaceutical services, which is attributed to its stron...

At which locations are the company’s products manufactured?

**Production Sites:** - China - USA - Germany WuXi AppTec Co., Ltd. operates a variety of production and research sites worldwide. The headquarters and most production facilities are located in China, where the company offers its extensive services in the areas of research, development, and product...

What strategy does WuXi AppTec pursue for future growth?

**Focus on Global Expansion:** WuXi AppTec has continuously expanded its presence in international markets in recent years. **Investments in R&D:** The company heavily invests in research and development to expand its services in the biotechnology and pharmaceutical sector. **Partnerships and...

Which raw materials are imported and from which countries?

**Imported raw materials/materials:** Chemicals, biological reagents, laboratory equipment **Main importing countries:** USA, Germany, Japan WuXi AppTec Co., Ltd. is a leading company in the field of biopharmaceutical research and development. The company imports a variety of raw materials and mat...

How strong is the company’s competitive advantage?

**Market share in the industry:** 10% (estimated, 2025) **R&D expenses:** 1.2 billion USD (2024) **Customer retention rate:** 85% (2025) WuXi AppTec Co., Ltd. has a significant competitive advantage in the biopharmaceutical industry, supported by several factors. The company has an estimate...

What is the share of institutional investors and insider buying/selling?

**Institutional investor share:** approx. 65% (2025, estimated) **Insider purchases/sales:** No significant transactions in the last quarter (2025, estimated) The institutional investor share in WuXi AppTec Co., Ltd. is estimated to be around 65%, based on the typical ownership patterns of large p...

What percentage market share does WuXi AppTec have?

**Market share of WuXi AppTec:** Estimate 12% (2025, based on market analysis) **Top competitors and their market shares:** 1. Thermo Fisher Scientific: 15% 2. Charles River Laboratories: 10% 3. Lonza Group: 9% 4. Catalent Inc.: 8% 5. Eurofins Scientific: 7% 6. WuXi AppTec: 12% 7. LabCorp: 6% 8. IC...

Is WuXi AppTec stock currently a good investment?

**Revenue growth:** 20% (2024) **Profit growth:** 18% (2024) **R&D expenses:** 10% of revenue (2024) WuXi AppTec Co., Ltd. recorded strong revenue growth of 20% in 2024, driven by increasing demand for its services in pharmaceutical research and development. The company has strengthened i...

Does WuXi AppTec pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.4% (2025, estimated) **Dividend history:** Continuous payout over the last 5 years WuXi AppTec Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently around 1.4%, indicating a moderate payout policy. Over the past...

New support ticket

Explore

WuXi AppTec Stock Value

WuXi AppTec Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does WuXi AppTec do?

WuXi AppTec Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

WuXi AppTec Stock Value

WuXi AppTec Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does WuXi AppTec do?

WuXi AppTec Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.